Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors by GlobeNewsWire | Feb 20, 2024 | Globe Newswire | 0 comments Leave a ReplyCancel reply